BLPH Bellerophon Therapeutics Inc.

0.69
0  -1%
Previous Close 0.69
Open 0.69
Price To Book 9.8
Market Cap 40254132
Shares 58,679,492
Volume 55,791
Short Ratio
Av. Daily Volume 505,191

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released January 7, 2019 with Cohort 2 and 3 data due later in 2019.
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 3 trial stopped due to futility - August 7, 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 trial met primary endpoint - noted September 5, 2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2 trial to be initiated YE 2018 with data due 2019.
INOpulse delivery device
Pulmonary hypertension associated with Sarcoidosis (PH-Sarcoidosis)